Insider Selling: Addus HomeCare (NASDAQ:ADUS) EVP Sells 284 Shares of Stock

Addus HomeCare Corporation (NASDAQ:ADUS) EVP Roberton James Stevenson sold 284 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total value of $29,922.24. Following the completion of the sale, the executive vice president owned 14,030 shares of the company’s stock, valued at $1,478,200.80. This trade represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Roberton James Stevenson also recently made the following trade(s):

• On Tuesday, February 24th, Roberton James Stevenson sold 567 shares of Addus HomeCare stock. The shares were sold at an average price of $107.35, for a total value of $60,867.45.

Addus HomeCare Stock Performance

NASDAQ:ADUS traded down $3.58 during mid-day trading on Thursday, hitting $104.02. 269,378 shares of the company traded hands, compared to its average volume of 239,147. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. The stock’s fifty day moving average price is $109.57 and its 200-day moving average price is $113.08. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 19.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.91. Addus HomeCare Corporation has a one year low of $88.96 and a one year high of $124.43.

Hedge Funds Weigh In On Addus HomeCare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC grew its stake in Addus HomeCare by 395.7% during the fourth quarter. Global Retirement Partners LLC now owns 233 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares in the last quarter. Larson Financial Group LLC lifted its stake in Addus HomeCare by 133.3% in the 3rd quarter. Larson Financial Group LLC now owns 238 shares of the company’s stock worth $28,000 after purchasing an additional 136 shares in the last quarter. Acumen Wealth Advisors LLC bought a new position in shares of Addus HomeCare during the 4th quarter valued at about $29,000. Private Trust Co. NA grew its position in shares of Addus HomeCare by 65.5% during the fourth quarter. Private Trust Co. NA now owns 283 shares of the company’s stock valued at $30,000 after purchasing an additional 112 shares in the last quarter. Finally, Arax Advisory Partners increased its holdings in shares of Addus HomeCare by 95.8% in the fourth quarter. Arax Advisory Partners now owns 280 shares of the company’s stock worth $30,000 after purchasing an additional 137 shares during the last quarter. Institutional investors own 95.35% of the company’s stock.

Addus HomeCare News Roundup

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: Q4 earnings/earnings call emphasized continued revenue growth, margin-leverage opportunities and an M&A-driven growth strategy for 2026 — supports longer‑term earnings upside. Addus HomeCare Earnings Call Highlights Growth And Scale
• Positive Sentiment: Stephens trimmed its price target from $140 to $135 but kept an “overweight” rating — the new target implies meaningful upside from current levels, indicating analyst confidence in the company’s outlook despite the cut. Stephens price target note
• Neutral Sentiment: Addus will participate in the Raymond James Institutional Investors Conference (investor visibility event; typically neutral but can aid liquidity/coverage). Conference participation
• Neutral Sentiment: Some published short‑interest data in the feed shows zero shares (data glitch/inconsistent reporting across sources) — treat those specific zero figures with caution. MarketBeat ADUS page
• Negative Sentiment: Significant insider selling over Feb. 24–25: CEO R. Dirk Allison sold two blocks (4,988 and 2,364 shares) and multiple senior EVPs sold smaller blocks across the two days — coordinated insider sales can pressure sentiment even if individual sales are routine and pre‑planned. See CEO filing. CEO insider-sale SEC filing
• Negative Sentiment: Short interest rose earlier in February (as of Feb. 13 there were ~1.15M shares short, ~6.5% of shares outstanding and ~4.6 days‑to‑cover) — elevated short activity can amplify downward price moves. Short interest data

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ADUS shares. Weiss Ratings restated a “hold (c+)” rating on shares of Addus HomeCare in a research note on Wednesday, January 21st. KeyCorp restated an “overweight” rating on shares of Addus HomeCare in a research report on Wednesday. Royal Bank Of Canada restated an “outperform” rating and set a $139.00 target price on shares of Addus HomeCare in a research note on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Addus HomeCare in a report on Wednesday, November 5th. Finally, Stephens decreased their price target on Addus HomeCare from $140.00 to $135.00 and set an “overweight” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Addus HomeCare has a consensus rating of “Moderate Buy” and an average price target of $134.33.

Addus HomeCare Company Profile

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.